-
Curious about #obinutuzumab (anti-CD20) in#lupus#nephritis? Well...we don't know much
about the results
of the "Nobility" phase 2 trial... so it is a bit early to be really enthusiastic
(but #FDA has granted a breakthrough therapy designation). Let's wait
and see.pic.twitter.com/JphpLVU4iP
-
FAQ during my lectures on
#CLL therapy: what is the value of the different#venetoclax combinations, with#obinutuzumab (Ven-Obi) or#ibrutinib (Ven-Ibru)? Therefore, I produced a Table with an ITT-based reporting of peripheral blood#MRD values (as per@iwCLL 2018 guidelines).pic.twitter.com/zpXkB2CXjx
-
Please stop by our poster (280) on the results of the safety run of our phase2 GATA study
#venetoclax#obinutuzumab#atezolizumab from@LysaLymphoma for R/R#DLBCL#FL pts#15ICML in Lugano. See you today and tomorrow at 12:30 in front of the poster
pic.twitter.com/MBRZcHtOXn
Prikaži ovu nit -
Fixed duration
#Venetoclax-#Obinutuzumab vs Chl-O. 432 pts. median age 72y. median CIRS-G 8. PFS HR 0.35. Benefit in high risk#CLL. No OS benefit but fup relatively short. 3m post Rx MRD-ve PB (75.5% vs 35.2%)+BM (56.9% vs. 17.1%) Congrats@HallekMichael+colleagues#blooducationpic.twitter.com/Jv0u4l9GXx
-
Dr Kirsten Fischer of
@UKKoeln presented an update of the#CLL14 protocol this morning. Long-lasting remissions in#CLL14 patients achieving#mrd negative remissions at EOT with#venetoclax &#obinutuzumab.#GCLLSG#ASH19#Leukemiapic.twitter.com/gNDoHgbIk2
-
The
@US_FDA has granted Breakthrough Therapy designation to#obinutuzumab, a CD20-directed cytolytic antibody, for the treatment of adults with#lupusnephritis.http://ow.ly/pySv50wmDyj -
The
#FDA has granted a Breakthrough Therapy Designation (#BTD check FDA website https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy …) for#obinutuzumab in#Lupus#Nephritis Link to press release: https://www.roche.com/dam/jcr:18a16d34-45da-45a4-a2f8-59fd9acd06ec/en/18092019-mr-gazyva-lupus-nephritis-btd-en.pdf … -
Interesting paper: why
#antiCD20#obinutuzumab is better in#CLL and#FL but not in#DLBCL - but not the whole story http://www.bloodjournal.org/content/early/2017/06/02/blood-2017-03-771832 …pic.twitter.com/nqXVdzp4kJ
-
#venetoclax-#obinutuzumab or#venetoclax-#ibrutinib in 1L#CLL ? Its like a haematologists version of the Messi vs Ronaldo debate... Amazing times in#CLL.#blooducation#CLL14#CLLsmpic.twitter.com/sEC88BZlYT
-
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin
#Lymphoma Who Received#Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study#lymsm http://ascopubs.org/doi/pdf/10.1200/JCO.2017.76.3656 … -
GALLIUM trial Follicular
#Lymphoma, when analyzing by chemo, the advantage of#obinutuzumab remains only in Bendamustine arm#ICML2017pic.twitter.com/Sc2GltF0X0
-
Le Gouill et al 15 pts 1L
#obinutuzumab+#venetoclax+#ibrutinib in#mantle cell lymphoma Potent combination All pts responded by end C2 6/8 MRD neg BM 8/8 MRD neg PB Good safety profile Look forward to seeing combination studied further in 1L pts#ASH19#lymsmpic.twitter.com/0c2ibABXSC
-
Results of Phase III GADOLIN trial of
#obinutuzumab for follicular#lymphoma - w/ M Trneny: http://ow.ly/t5j7301y9SF#immunotherapy#lymsm -
Obinu&$@&mab superior to rituximab in B cell depletion without apparent increase in immunodeficiency side effects. Would be nice to see a side by side comparison in future trials, rather than placebo control.
#obinutuzumab#kidneywkpic.twitter.com/fEtT1igupQOvo je potencijalno osjetljiv multimedijski sadržaj. Saznajte više
-
#OpiniónPositiva de la@EMA_News para#venetoclax +#obinutuzumab en el tratamiento de la leucemia linfocítica crónica#LLC no tratada previamentehttps://www.ema.europa.eu/en/medicines/human/summaries-opinion/venclyxto-0 … -
Important data suggesting good therapeutic efficacy of
#venetoclax plus#obinutuzumab in high risk#CLL.@UKKoeln#leusm#leukemia#gcllsghttps://twitter.com/chanyooncheah/status/1222177152008740864 …
-
#Venetoclax +#obinutuzumab just approved frontline for#CLL in Brazil. Important option for patients not eligible for intensive Tx. Nice to see quicker regulatory approvals in Brazil. Interesting how all will be incorporated into practice.#CLLSM@US_FDA@EMA_News@MOCBrasil -
proud to discuss
#lenalidomide and#rituximab therapy for elderly patient with indolent#lymphoma, followed by@DrNathanFowler with lenalidomide plus#obinutuzumab at#ASH2019pic.twitter.com/pFwDSsnMWQ
-
Positive trials
#lupus#nephritis ! Finally!#voclosporin#obinutuzumab. Awaiting#BlissLN@LUPUSUK@Lupusreference@rasprclub@RenalAssoc@BritRenalSoc@Kidney_Research@1mariecondon@megan_griffith1 Congrats@BradRovin@AuriniaPharmaPrikaži ovu nit -
On the heme consult service now and helping to look into
#obinutuzumab approval as an inpatient... not for CLL but for lupus nephritis! Rheum and heme may disagree on HLH management, but this is a pretty impressive (albeit
) convergence of fields!
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.